JPRN-UMIN000003945已完成1 期
A phase 1 study of adoptive immunotherapy using autologous RNF43 peptide pulse dendritic cells and RNF43 peptide specifically activated lymphocytes in patients with advanced solid tumors - RNF43 peptide pulse DC with specifically activated lymphocytes therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with severe pre-exiting diseases :autoimmune diseases, an active infectious diseases, cardiovascular disorders, respiratory disorders, renal dysfunction, immunodeficiency, and hematological disorders. 2.Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner 3.No active brain metastases. 4.Patients who should receive systemic administration of steroid or immunosuppressive agents. 5.Inappropriate for study entry judged by an attending physician.
研究者
相似试验
未知
1 期
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
未知
1 期
Phase I/II study of adoptive immunotherapy using predetermined minor histocompatibility antigen-specific cytotoxic T cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantation.1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000161Aichi Cancer Center30
已完成
不适用
Phase I/IIa Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With PSA biochemical failure after radical prostatectomy.JPRN-UMIN000006617Tokyo Women's Medical University10
进行中（未招募）
1 期
Clinical study with autologous CIK cells for patients with advanced and uresectable sarcomapatients with advanced and non-resectable sarcomaMedDRA version: 20.0Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002257-11-ITAOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO35
已完成
不适用
Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell CarcinomaCytokine refractory Renal cell carcinomaJPRN-UMIN000004482Tokyo Women's Medical University35